RT Journal Article
SR Electronic
T1 Five years functional connectivity reorganization without clinical or cognitive decline in MS
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.19.20135558
DO 10.1101/2020.06.19.20135558
A1 Einar August Høgestøl
A1 Samuele Ghezzo
A1 Gro Owren Nygaard
A1 Thomas Espeseth
A1 Piotr Sowa
A1 Mona K. Beyer
A1 Hanne Flinstad Harbo
A1 Lars T. Westlye
A1 Hanneke E. Hulst
A1 Dag Alnæs
YR 2020
UL http://medrxiv.org/content/early/2020/06/20/2020.06.19.20135558.abstract
AB Objective 1) To assess fMRI-based functional connectivity (FC) anomalies in early multiple sclerosis (MS), 2) To determine the relation between FC changes and structural brain damage due to disease progression 3) To study the association between FC changes and cognitive and physical disability.Methods Structural MRI and resting-state fMRI were acquired from 76 early relapsing-remitting MS patients at baseline (average disease duration 71.7 months ± 63) and after five years. Ninety-four healthy controls (HCs) matched for age and sex were included at baseline. Independent component analysis (ICA) and network modelling were used to measure FC. FC variation was related to expanded disability status scale and neuropsychological outcomes. Brain and lesion volumes were quantified using standard methods. We used the 25 independent components obtained from ICA to estimate the longitudinal stability of the brain connectome as a proxy for functional reorganization over time.Results The MS subjects were clinically and cognitively stable. Compared to HCs, FC abnormalities were detected within networks and in single connections in patients with early MS at baseline. Over time, FC was relatively invariable, but changes in FC were associated with progression of brain atrophy (ρ = 0.39, p = .06). No significant relationship with clinical and cognitive measures or lesion load was detected.Conclusion Patients with MS showed evidence of altered FC in the early stages of the disease. Over time, changes in FC seem to be related to a progression of brain atrophy, which are known to precede changes in clinical and cognitive functioning.Competing Interest StatementE. A. Hϕgestϕl has received honoraria for lecturing from Biogen, Merck and Sanofi-Genzyme, and unrestricted research support from Merck and Sanofi-Genzyme. P. Sowa has received honoraria for lecturing and travel support from Merck. M. K. Beyer has received honoraria for lecturing from Novartis and Biogen Idec. H.F Harbo has received travel support, honoraria for advice or lecturing from Biogen Idec, Sanofi-Genzyme, Merck, Novartis, Roche, and Teva and an unrestricted research grant from Novartis. Hanneke Hulst received honoraria for speaking at scientific meetings, serving at scientific advisory boards and consulting activities from Biogen, Celgene, Genzyme, Merck and Roche. She has received research support from the Dutch MS Research foundation and serves on the editorial board of Multiple Sclerosis Journal (MSJ). S. Ghezzo, G.O. Nygaard, T. Espeseth, L.T. Westlye and D. Alnæs report no disclosures.Funding StatementThe project was supported by grants from the South-Eastern Health Authorities of Norway (grant number 2011059/ES563338/Biotek 2021) and by the European Union under the Horizon 2020 programme (grant number 733161).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The project was approved by the regional ethical committee of South Eastern Norway (REC ID: 2011/1846, 2016/102 and 2009/2070), and all participants received oral and written information and gave their written informed consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSummary data as published in this paper will be available, but other data are not publicly available because of patient privacy restrictions decided by the Regional Ethical Committee. We may apply for permission to share data with new collaborators, still adhering to patient privacy requirements of the Law of Health Research. All code needed to replicate our described analyses is available upon request from the corresponding author.